WAVEMAN · COMPANY

CASIF · Casi Pharmaceuticals, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

CASIF

Name: CASI Pharmaceuticals, Inc. (CASIF) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

CASI Pharmaceuticals, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001962738

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-27.4%

XBRL, annual

NET MARGIN

-232.0%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

1 fund added or opened last quarter

REVENUE

-27.4% year over year

below 76% of Pharma & Biotech

MARGIN

-232.0% net margin

below 74% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

0.7% of shares outstanding short · 87.0 days to cover · settled 2026-07-31

below 76% of Pharma & Biotech

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 1 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for CASI Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

WEST PACES ADVISORS INC.

100.0 sh

$17

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Clinical pipeline

ClinicalTrials.gov · 6 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 2

0 ACTIVE

Multi-phase

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$20.7M	$28.5M	$33.9M	$38.0M
GROSS PROFIT	$10.1M	$11.1M	$20.1M	$27.3M
OPERATING INCOME	$-45.0M	$-39.6M	$-25.1M	$-34.0M
NET INCOME	$-48.1M	$-39.3M	$-27.0M	$-41.0M
EPS (DILUTED)	-2.59	-2.56	-2.02	-3.01
OPERATING CASH FLOW	$-20.8M	$-29.2M	$-20.0M	$-21.1M
CASH	$5.6M	$13.5M	$17.1M	$47.1M
LONG-TERM DEBT	—	—	$18.9M	—
BUYBACKS	—	—	$278.0K	$3.3M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE